Sortera bio

Sortera Bio is an early-stage biotech leveraging its proprietary Deep Screening platform to solve the critical data generation bottleneck in AI-driven drug discovery. By experimentally measuring hundreds of millions of sequence-function pairs in a single run, the company creates the large, unbiased datasets required to build predictive AI models for biologics design. This approach has attracted a strategic collaboration with AstraZeneca and £7.5M in pre-seed funding, positioning Sortera as a promising player in the next generation of drug discovery tools. The company is led by a technically strong team with deep expertise in molecular biology, microfluidics, and AI, and is based in the Cambridge, UK biotech cluster.

Deep Screening: An integrated experimental and computational platform that generates hundreds of millions of sequence-function data points from a single experiment to train AI models for biologics design.

Sortera operates in a competitive space that includes other AI-native drug discovery companies (e.g., Absci, Generate Biomedicines), large life science tools companies with screening capabilities (e.g., 10x Genomics, Berkeley Lights), and internal efforts at major pharma. Its differentiation hinges on the unprecedented scale and quality of its functional data generation, which is claimed to be a key bottleneck for competitors.